Ultrasound and digital breast tomosynthesis find more cancers than just 2D mammography.
Ultrasound and digital breast tomosynthesis (DBT) detect more cancers than 2D mammography alone, according to a study published in The Breast.
Researchers from Korea sought to determine the percentage of breast cancers detected by screening ultrasound that were detectable by full-field digital mammography (FFDM) and DBT.
A total of 84 women with negative mammograms, but who had breast cancer subsequently detected by ultrasound were initially included in the study. All underwent both FFDM and DBT. Forty-one women were left in the study after the researchers excluded women with overt suspicious findings on repeat mammography and ineligible cases. Three radiologists, blinded to tumor location, read the images.[[{"type":"media","view_mode":"media_crop","fid":"41850","attributes":{"alt":"breast imaging","class":"media-image media-image-right","id":"media_crop_1507659893221","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4482","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 150px; width: 150px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"©karelnoppe/Shutterstock.com","typeof":"foaf:Image"}}]]
In the unblinded review, there were 25 visible cancers (61%) on FFDM and 34 (82.9%) on DBT. However, with the blinded reviews, the radiologists detected 22 (53.7%) on DBT and 11 (26.8%) on FFDM. “The dominant lesion type was “focal asymmetry” on DBT (39.0%) and “asymmetry” on FFDM (31.7%),” the authors wrote.
The authors concluded that both ultrasound and DBT detected more than half of cancers not found on 2D mammography, with an additional 29% of cancers visualized on DBT, when the radiologists were aware of the area of concern.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.